![maxim dl pro suite 5.08 maxim dl pro suite 5.08](https://windows-cdn.softpedia.com/screenshots/MaxIm-DL_4.png)
In the first cohort they received single oral doses of methylone (50 mg and 100 mg and placebo), the second cohort increased the dose of methylone to 150 mg. Doses of methylone will start at 50 mg until 300 mg. Each subject participates in one cohort that includes three experimental sessions. Participants were healthy males with recreational experience in psychostimulants. The study includes three different cohorts of 3 subjects, the doses of methylone increased after the evaluation of the safety and pharmacological effects. Methods: The design of the study is double-blind, placebo-controlled, crossover and randomized (lower doses were allocated before the higher dose for safety reasons). All treatment-emergent adverse events were transient and of mild/moderate intensity with no other treatment-related effects apparent. Unbound daridorexant PK in Child A patients did not differ on PK from healthy subjects. Compared to healthy subjects, Child B patients had a higher AUC (1.60 ), a lower apparent plasma clearance (0.63 ), and the same doubling in t½ as total daridorexant, while Cmax was unchanged. Considering the high plasma protein binding (>99%) and a 1.9-2.3-fold increase in the unbound fraction in patients with liver cirrhosis, the PK of unbound daridorexant were also assessed. Furthermore, the median time to reach Cmax (tmax) was slightly delayed (1.0 h in Child A, 0.5 h in Child B patients), while for Child B patients, a doubling in terminal half-life (t½) was observed (2.09 ). Results: Compared to healthy subjects, patients showed a decrease in total daridorexant area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) with a geometric mean ratio (GMR, 90% confidence interval ) of 0.51 (0.28-0.92) and 0.50 (0.35-0.72) in Child A and 0.74 (0.39-1.41) and 0.42 (0.29-0.60) in Child B patients, respectively.